Report interim data from the open label extension trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 25 Jul 2023
- Due
- 31 Dec 2024
- Delivered
- December 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“interim data expected in Q4 2024”
What we found
Evidence strength A What the grades mean
The company reported initial data from its ongoing open label study in December 2024, which falls within the Q4 2024 deadline.
-
A Larimar Therapeutics, Inc. 10-K filed 2026-03-19
“In December 2024, we reported initial data from our ongoing OL study.” ✓ confirmed on the page
Market reaction: the shares moved +9.5% against the S&P 500 over the three sessions around the disclosure (18 Mar 2026 to 23 Mar 2026). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 25 Jul 2023
Deadline 31 Dec 2024 (“in Q4 2024”) · wording expected
-
Version 2 · stated 14 Mar 2024
Deadline 31 Dec 2024 (“the fourth quarter of 2024”) · wording firm
“We remain on track to report interim data from the OLE study in the fourth quarter of 2024.”
-
Version 3 · stated 24 Feb 2026
Deadline 30 Jun 2026 (“Q2 2026”)
“Topline data Q2 2026”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Open label extension trial interim data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-LRMR-002966 · Corrections policy